What is the recommended dosing and monitoring protocol for oral urea in a patient with euvolemic hyponatremia (SIADH) after fluid restriction has failed?

Oral Urea for SIADH After Failed Fluid Restriction

For euvolemic hyponatremia (SIADH) refractory to fluid restriction, initiate oral urea at 15-30 grams per day, divided into 2-3 doses, with daily sodium monitoring until levels normalize above 130 mEq/L.

Dosing Protocol

Initial Dosing

• Start with 15-30 grams daily divided into 2-3 doses (e.g., 15g BID or 10g TID) 1, 2, 3
• For severe hyponatremia (Na <120 mEq/L), consider starting at 30g/day divided TID or QID 3
• Alternative dosing: 0.25-0.50 g/kg/day 4
• Can be dissolved in 100-150 mL normal saline if needed 1

Dose Escalation

• If inadequate response after 2-3 days with 15g/day, increase to 30g/day 2, 5
• Some patients may require up to 40g every 8 hours in acute settings 1
• Maximum studied doses reach 30-40g/day in divided doses

Duration

• Continue until sodium normalizes (≥135 mEq/L) 4, 2
• Median treatment duration: 5-7 days for acute correction 4, 3
• May require long-term therapy (months to years) for chronic SIADH 5, 6

Monitoring Protocol

Frequency

• Baseline: Serum sodium, urine sodium, urine osmolality, serum osmolality, volume status 1
• First 24-48 hours: Check sodium every 12-24 hours 4, 2
• After stabilization: Daily sodium until normalized, then as clinically indicated 1
• Outpatient: Recheck at 7-10 days initially 2

Expected Response

• First 24 hours: Expect 2-4 mEq/L increase 4, 3, 7
• 72 hours: 64% achieve sodium ≥130 mEq/L 2
• Time to normalization: Median 3-6 days 4, 3, 7

Safety Targets

• Avoid overcorrection: Do not exceed 8 mEq/L increase in 24 hours 1
• Severe symptoms: May correct 6 mEq/L over first 6 hours, then limit to 2 mEq/L over next 18 hours 1
• No cases of osmotic demyelination reported in urea studies 4, 2, 3

Clinical Context and Evidence Strength

The neurosurgical guidelines [1-1] recommend oral sodium chloride 100 mEq TID as an add-on therapy when fluid restriction fails, but recent high-quality evidence strongly supports urea as superior. A 2024 meta-analysis 8 demonstrated urea increases sodium by mean 9.08 mEq/L (95% CI 7.64-10.52), with greater efficacy in severe hyponatremia (18.04 mEq/L increase when Na <120 mEq/L). A 2024 comparative study 7 showed urea normalized sodium in 59.8% of patients versus only 42% with fluid restriction (p=0.007), with significantly lower 60-day mortality (16.1% vs 32.8%, p<0.007).

Tolerability and Side Effects

Distaste is the primary limitation (reported in 22-54% of patients) 4, 2, but rarely leads to discontinuation (<10% of cases). Strategies to improve palatability:

• Mix with juice or flavored beverages
• Divide into smaller, more frequent doses
• Use cold liquids to mask taste
• Consider nasogastric administration if oral intolerance persists 3

No serious adverse events, hypernatremia, or overcorrection reported across studies 4, 2, 3, 8.

When to Use Urea vs. Alternatives

Choose urea when:

• Fluid restriction (<1-1.5L/day) fails after 48-72 hours 1, 2
• Sodium remains <130 mEq/L despite compliance 4
• Patient cannot tolerate severe fluid restriction
• Cost is a consideration (urea is inexpensive compared to vaptans) 2, 9

Consider vaptans instead when:

• Rapid correction needed in hospitalized patients (though urea works within 24 hours) 9
• Patient cannot tolerate urea taste despite interventions
• Cost is not prohibitive

Urea performs comparably to vaptans (MD -1.96 mEq/L, p=0.1) but is far less expensive and has no risk of hepatotoxicity 8.

Common Pitfalls

1. Starting too low: 15g/day may be insufficient for severe hyponatremia; start at 30g/day if Na <120 mEq/L 3
2. Inadequate monitoring: Check sodium at 24 hours to assess response and adjust dosing 4
3. Premature discontinuation: Continue until sodium normalizes, not just improves 2
4. Ignoring volume status: Confirm euvolemia before diagnosing SIADH; urea is contraindicated in hypovolemic hyponatremia 1
5. Forgetting dietary solute: Some patients need increased protein/salt intake alongside urea 1, 5

Special Populations

Neurosurgical patients: Urea is particularly effective and well-tolerated in SAH patients with SIADH, correcting sodium to >130 mEq/L within median 1 day and >135 mEq/L within 3 days 3

Oncology patients: Safe for long-term use in cancer-associated SIADH, with 21% able to discontinue after cancer treatment 6

Cirrhosis: The 2025 AGA guidelines 10 do not recommend urea for hypervolemic hyponatremia in cirrhosis—this is a different pathophysiology requiring sodium/fluid restriction and potentially albumin or vasoconstrictors